Publications

You are here:

Home
Publications

* Click the link below to download

NDA Risk management Policy

2021-10-12

Pharmacovigilance Bulletin Volume 12: issue 4

2021-03-09

NDA Annual pharmacovigilance report 2019/2020

2021-01-25

Pharmacovigilance-Bulletin-June-2020

2020-07-30

Product applications with incomplete submission recommended for dismissal

2020-07-15

Pharmacovigilance guidelines for licensed persons, pharmaceutical companies, and market authorization holders

2020-07-14

Caution against stockpiling and irrational use of medicine

2020-03-27

Pharmacovigilance strategy for Uganda

2020-01-22

Certification of premises used to supply restricted drugs within institutions conducting clinical trials

2018-08-14

Licensing of pharmacies in private hospitals and medical centers

2018-07-31

Signed joint Communique

2018-07-31

Detection of Impurity in the Active Pharmaceutical Ingredient (API) valsartan manufactured by Zhejiang Huahai Pharmaceuticals, Linhai, China

2018-07-5

Step wise guide for Product retention on NDAMIS.

2018-07-5

Addendum to 2018 Guidelines for the renewal of licenses for pharmacies

2018-07-5

CIRCULAR NO 12 - MARKET AUTHORIZATION HOLDERS

2018-05-8

Stategic Plan 2016-2021

2018-03-14

Presentation on the counterfeit hepatitis B.

2018-03-14

Fact sheet on NDA as at January 31st 2018

2018-02-02

List of variations to be applied for on NDAMIS.

2018-01-18

Premise licensing statistics (2018) as at 27th December 2017

2017-12-29

Investigational product meeting with Researchers Dec 2017

2017-12-11

Good Clinical Practice Principles

2017-12-11

Good Documentation Practices in research 8 Dec 17

2017-12-11

NDA 8th DEC 2017

2017-12-11

New registration numbers (NDAMIS numbers) for Veterinary Drugs

2017-11-15

New registration numbers (NDAMIS numbers) for Herbal Medicines

2017-11-15

New registration number (NDAMIS numbers) for the retained products

2017-11-15

Published EBATIC Paper sept 2017

2017-08-04